Antimicrobial Susceptibility Testing Symposium and Therapeutic Drug Monitoring Workshop


We regret to advise that this event has been postponed because of COVID-19. Please contact us if you have registered previously and have not been reimbursed.

We hope to deliver a completely virtual program on TDM on Wednesday, 11 November 2020, and Antimicrobial Susceptibility testing 1-day seminar is proposed for later in the week. Further details will be provided as they become available.

Strong associations exist between drug exposure and patient outcome for many antimicrobials. Therapeutic drug monitoring (TDM) is an obvious method to apply to ensure more patients achieve effective drug concentrations, and should be considered standard-of-care for most antimicrobials. However, there remains uncertainty and inconsistency with practice for which patients would most benefit from TDM, which antimicrobial concentration targets should be used and what feasible methods could be applied to effectively change doses. In this workshop, we will address these issues as they relate to antibacterials, antifungals and antimycobacterials. We will also present new technological advances that improve the feasibility and accuracy of antimicrobial TDM and specific considerations for key settings including paediatrics and outpatients (and critically ill patients of course!) as well as the place of dosing software. Please join us and hear from leading practitioners and scientists in this area!

Antimicrobial Therapeutic Drug Monitoring Workshop

Wednesday, 11 November 2020, Proposed Virtual Event

Preliminary Workshop Programme
Time Topic Speaker
0830-0900 Registration  
Session 1: Dose Optimisation and PK-PD                                                                                                                                                             Chair Prof Jason Roberts
0900-0905 Welcome Prof Jason Roberts (Brisbane)
0905-0925 The need for antimicrobial dose optimisation Prof Jason Roberts (Brisbane)
0925-0940 Different approaches to antimicrobial dose optimisation Mr Paul Williams (Sunshine Coast)
0940-1000 Antibacterial pharmacokinetic-pharmacodynamic targets Dr Kathryn Daveson (Canberra)
1000-1020 Antifungal pharmacokinetic-pharmacodynamic targets Ms Karen Urbancic (Melbourne)
1020-1040 Antimycobacterial pharmacokinetic-pharmacodynamic targets Dr Andrew Burke (Brisbane)
1040-1100 Morning Tea
Session 2: Therapeutic Drug Monitoring Concepts Chair Prof Gunnar Kahlmeter
1100-1120 Principles of therapeutic drug monitoring (TDM) A/Prof Darren Roberts (Sydney)
1120-1140 Outcome and cost-effectiveness data supporting antimicrobial TDM Dr Gloria Wong (Brisbane)
1140-1200 Considerations for TDM in paediatrics Dr Amanda Gwee (Melbourne)
1200-1220 Antimicrobial susceptibility testing considerations for TDM Prof John Turnidge (Adelaide)
1220-1240 Study design considerations to quantify the clinical value of TDM Prof Jan-Willem Alffenaar (Sydney)
1240-1330 Lunch
Session 3: Dosing Software Chair Prof Jan-Willem Alffenaar (Sydney)
1330-1350 Use of TDM in the outpatients setting Dr Kate McCarthy (Brisbane)
1350-1410 Technological advances to revolutionise TDM: Sampling and Bioanalytics Dr Suzanne Parker (Brisbane)
1410-1430 Technological advances to revolutionise TDM: Dosing software Dr Os Cotta

IDS-ODS Dosing Software

IDS-ODS case studies: vancomycin and meropenem

Mr Paul Williams (Sunshine Coast)
1545-1615 Afternoon tea
Session 4: Research Priorities Chair Prof Jeffrey Lipman
1615-1715 Panel Discussion: Research Priorities for TDM Prof Jason Roberts (Brisbane)
1715 Close Prof Jason Roberts (Brisbane)

Antimicrobial susceptibility testing is a key component of the management of patients with bacterial and fungal infections.  In the setting of increasing prevalence of multi-drug resistant organisms, susceptibility testing is crucial.  The aim of this workshop is to provide an opportunity to understand the process of susceptibility testing along with the rationale for setting breakpoints, epidemiologic cutoffs and the potential for new AST methods to improve clinical care.

This 2-day symposium will provide an opportunity to improve your knowledge and understanding of how to apply susceptibility testing.  In addition, an extra opportunity will be available for a small cohort of 24 people to spend a half-day in the laboratory performing and interpreting susceptibility testing by common methods.

Speakers include Prof John Turnidge - EUCAST Scientific Secretary and ACSQHC Senior Clinical Advisor and

Dr Gunnar Kahlmeter - MD, EUCAST Steering committee and Head of the EUCAST Development Laboratory

Antimicrobial Susceptibility Testing Symposium

Thursday, 12 November 2020 Proposed Virtual Event

Laboratory workshop session - Wet Lab

Laboratory session schedule
Time Activity (All) Group 1 Group 2 Group 3 Group 4
0830-0900 Registration  
0900-0915 Welcome and introduction to AST
0915-0945   BMD setup Etest; Disk setup Lecture: Commercial AST methods
0945-1015 Etest; Disk setup BMD setup
1015-1045 Morning Tea
1045-1115   Lecture: Commercial AST methods BMD setup Etest; Disk setup
1115-1145   Etest; Disk setup BMD setup
1145-1200   Reading AST BMD, Disk and Etest Lecture: Reading AST
1200-1215   Lecture: Reading AST Reading AST BMD, Disk and Etest
1215-1230 Conclusion and final comments

Antimicrobial Susceptibility Testing Symposium

Thursday, 12 November 2020 Proposed Virtual Event

AST Symposium - Thursday afternoon

Preliminary Symposium Programme
Time Topic Speaker
1200-1330 Lunch and registration
1330-1350 Welcome, introduction and housekeeping Dr Andrew Henderson (Brisbane)
1350-1430 Keynote presentation - Harmonising breakpoints Prof Gunnar Kahlmeter (Sweden)
1430-1500 Australian perspectives of AST: where we have come from to where we are now Prof John Turnidge (Adelaide)
1500-1530 Afternoon Tea
1530-1600 Resistance detection by WGS: how does it help the clinician? Dr Patrick Harris
1600-1630 Applying and understanding new EUCAST categories: I and the ATU Prof Gunnar Kahlmeter (Sweden)
1630-1700 Revised aminoglycoside breakpoints Prof John Turnidge (Adelaide)

AST Symposium - Friday 13 November

Preliminary Symposium Programme
TIme Topic Speaker/Facilitator
0830-0930 Ask the EUCAST expert Prof Gunnar Kahlmeter and Prof John Turnidge
0930-1030 AST in clinical trials Dr Andrew Henderson
1030-1100 Morning Tea
1100-1145 ECOFF - what, how and why? Prof Gunnar Kahlmeter and Prof John Turnidge
1145-1230 Therapeutic window: MIC, dosing and tolerability Prof Jason Roberts
1230-1330 Lunch
1330-1400 MIC variability including ISO-20776:1 & 2: Background and updates of revised guidelines Prof John Turnidge
1400-1430 Implementing AST in the laboratory Dr Jenny Robson
1430-1445 EUCAST/CLSI categories: similiarities and differences Dr John Iredell
1445-1500 Disk diffusion RAST - EUCAST method  Prof Gunnar Kahlmeter
1500-1530 Afternoon Tea
1530-1600 MTB AST testing Dr Chris Coulter
1600-1630 Fungal AST testing Dr Sarah Kidd

AST Symposium - Saturday 14 November

Preliminary Symposium Programme
Time Topic Speaker/Facilitator
0900-0930 Quality control of AST Dr Claire Heney
0930-1000 Developing new antimicrobials: screening of novel compounds Dr Mark Blaskovich
1000-1030 The role of EUCAST in setting breakpoints for new drugs Prof Gunnar Kahlmeter
1030-1100 Morning Tea
1100-1130 MDR and XDR gram negatives and new treatments. Overview and mechanisms of resistance Prof David Paterson
1130-1200 The role of laboratory automation in AST: good, bad and ugly Dr John Iredell
1200-1230 Closing remarks  
1230-1330 Lunch


Antimicrobial Susceptibility Testing Symposium and Therapeutic Drug Monitoring Workshop

Wed 11 Nov 2020 8:30amSat 14 Nov 2020 5:00pm




Luminita Vlad
07 3346 5045